I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, Mail Stop DD, P.O. Box 1436,

Alexandria, VA 22313 on December 16, 200

David Salewan chile

David R. Saliwanchik, Patent Attorney

INFORMATION DISCLOSURE STATEMENT

Examining Group not yet assigned Patent Application

Docket No. GJE-6089D3 Serial No. 10/679,723

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

not yet assigned

Applicant

Bruce Joseph Roser

Serial No.

10/679,723

Filed

October 6, 2003

For

Dried Blood Factor Composition Comprising Trehalose

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:


2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

DRS/la

Attachments: Form PTO/SB/08; copies of references cited therein.

H:\DOC\IDS\GJE\6089D3-pto.doc\DNB/la



PTO/SB/08A (08-03)

GJE-6089D3

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/679,723 INFORMATION DISCLOSURE **Filing Date** October 6, 2003 STATEMENT BY APPLICANT First Named Inventor Bruce Joseph Roser (use as many sheets as necessary) **Art Unit** Not yet assigned **Examiner Name** Not yet assigned Sheet of **Attorney Docket Number**

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	U1	US-4,495,175 A	Chavin et al.	1-22-1985		
	U2	US-4,758,657 A	Farb et al.	7-19-1988		
	U3	US-4,806,343 A	Carpenter et al	2-21-1989		
	U4	US-4,891,319 A	Roser	01-02-1990		
	U5	US-5,364,756 A	Livesey et al.	11-15-1994		
	U6	US-5,576,291	Curtis	11-19-1996		
	U7	US-6,649,386 B2	Roser	11-18-2003		
	U8	US-				
	U9	US-				

2

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code 3 - Number 4 - Kind Code5 (if known)			or Relevant Figures Appear	T ⁶
	F1	EP 0 314 095 A1	05-03-1989	Rorer International (Overseas) Inc.		
	F2	EP 0 475 409 A2	03-18-1992	Lifecell Corporation		
	F3	WO 87/00196	01-15-1987	Quadrant Bioresources Limited		
	F4	WO 94/07510 A1	04-14-1994	Kabi Pharmacia AB		
	F5	WO 95/01804	01-19-1995	Kabi Pharmacia AB		
	F6	WO 95/07713	03-23-1995	Baxter International		
	F7					

[Examiner	Date	
1		
I Signature I	I Considered I	
0.00.00	 Corrolativa	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

control number.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

Complete if Known **Application Number** 10/679,723 Filing Date October 6, 2003 **First Named Inventor** Bruce Joseph Roser **Group Art Unit** Not yet assigned Not yet assigned **Examiner Name** Attorney Docket Number G IF-6089D3

						Not yet assigned	
Shee	t	2	of	2	Attorney Docket Number	GJE-6089D3	
			NC	N PATENT LITER	RATURE DOCUMENTS		
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T²
	R1_	Cleland, J.L. et al. (ed) "Design and Development Strategies" Chapter 1 in Formulation and Delivery of Protein and Peptides, American Chemical Society Symposium Series (1994) 567:1-19.					
	R2	Roser, B. et a 4(8):47-53.	I. "Trehalose	e Drying: A Novel Re	placement for Freeze-Drying"	BioPharm (September 1991) vol.	
	R3						
	R4						
	R5						
	R6				2222		
	R7						
· .	R8						
	R9						
	R10						
	R11						
	R12						
	R13						

Examiner	Date
Cimmak	1
Signature	Considered
AEVALUATED 1111	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.